



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations

Vancouver, British Columbia – (August 11, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce the appointment of Thomas Malcolm, Ph.D., as Chief Scientific Officer and Head of U.S. Operations. Dr. Malcolm will be responsible for establishing and developing BioMark’s operations in the U.S.

“Tom is an excellent addition to our core management team, bringing us solid scientific expertise and an in-depth understanding of next-generation diagnostics powered by metabolomics,” said Rashid Ahmed, BioMark President and CEO. “A key aspect in our strategy is to expand into the U.S. market and Tom’s experience will be invaluable in this transformation. I welcome Tom to our team and we look forward to adding more critical members to our U.S. team under his leadership.”

“This is a great opportunity for me to be part of the new wave of diagnostic technologies utilizing metabolomics-based assays,” said Dr. Malcolm. “I believe that BioMark’s unique approach and technology platform will play an instrumental role in offering the medical community better and more economical tools to manage and treat cancers. BioMark’s team and scientific collaborators all bring immense global expertise and depth. It will be my privilege to join the team.”

Dr. Malcolm is founder and CEO of Criterion BioScience Capital Group, a growing New York-based pharmaceutical research company that provides scientific and business analysis to hedge funds and private investors. He previously was a senior biochemist at Siemens Healthcare Diagnostics, where he directed a team of research scientists for the development of ELISA-based diagnostic assays and was responsible for assay development, design and validation. Dr. Malcolm worked as a Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center and Mount Sinai School of Medicine, with a focus on the regulation of genes relating to various cancers. He graduated from the University of British Columbia with Ph.D. in Biochemistry and Molecular Biology, with a focus on gene regulation in viral models.

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark Diagnostics is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

Company Contact
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.

Investor Contact
LHA
Jody Cain
310-691-7100

604-282-6567
info@biomarkdiagnostics.com

Jcain@lhai.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.